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Abstract
Aims: Pulmonary oxygen toxicity contributes to lung injury in newborn and adult humans. We previously reported
that thioredoxin reductase (TrxR1) inhibition with aurothioglucose (ATG) attenuates hyperoxic lung injury in adult
mice. The present studies tested the hypothesis that TrxR1 inhibition protects against the effects of hyperoxia via
nuclear factor E2-related factor 2 (Nrf2)-dependent mechanisms. Results: Both pharmacologic and siRNA-mediated
TrxR1 inhibition induced robust Nrf2 responses in murine-transformed Clara cells (mtCC). While TrxR1 inhibition
did not alter the susceptibility of cells to the effects of hyperoxia, glutathione (GSH) depletion after TrxR1 inhibition
markedly enhanced the hyperoxic susceptibility of cultured mtCCs. Finally, in vivo data revealed dose-dependent
increases in the expression of the Nrf2 target gene NADPH:quinone oxidoreductase 1 (NQO1) in the lungs of ATG-
treated adult mice. Innovation: TrxR1 inhibition activates Nrf2-dependent antioxidant responses in mtCCs in vitro
and in adult murine lungs in vivo, providing a plausible mechanism for the protective effects of TrxR1 inhibition
in vivo. Conclusion: GSH-dependent enzyme systems in mtCCs may be of greater importance for protection against
hyperoxic exposure than are TrxR-dependent systems. The induction of Nrf2 activation via TrxR1 inhibition rep-
resents a novel therapeutic strategy that attenuates oxidant-mediated lung injury. Similar expression levels of TrxR1
in newborn and adult mouse or human lungs broaden the potential clinical applicability of the present findings to
both neonatal and adult oxidant lung injury. Antioxid. Redox Signal. 17, 1407–1416.
Introduction
Pulmonary oxygen toxicity contributes to the develop-ment of bronchopulmonary dysplasia (BPD) in prema-
ture infants and acute respiratory distress syndrome (ARDS)
in children and adults (5,9). Oxygen toxicity is likely medi-
ated through reactive oxygen and nitrogen species produced
at higher rates during hyperoxic exposure (3). While the
mechanisms responsible for oxygen-induced lung injury
have been extensively studied, clinically beneficial therapies
are lacking.
Thioredoxin reductase-1 (TrxR1) is a nicotinamide adenine
dinucleotide phosphate (NADPH)-dependent oxidoreduc-
tase that reduces the active site of cytosolic thioredoxin-1
(Trx1) from the disulfide form to the biologically active dithiol
form (1). Trx1 contributes to antioxidant activity by donat-
ing electrons to peroxiredoxins for the reduction of hydro-
gen peroxide (H2O2) (28,34), contributes to the synthesis of
Innovation
The present data indicate that thioredoxin reductase-1
(TrxR1) inhibition activates nuclear factor E2-related factor 2
(Nrf2)-dependent antioxidant responses in murine-trans-
formed Clara cells (mtCC) in vitro and in adult murine lungs
in vivo, providing a plausible mechanism for the protective
effects of TrxR1 inhibition in vivo in an adult murine hyper-
oxic lung injury model that was previously reported by our
group. Furthermore, our data indicate that thioredoxin-1
(Trx1) and TrxR1 are predominantly expressed by ciliated
and non-ciliated (Clara) conducting airway epithelial cells in
newborn human and newborn murine lungs, which is sim-
ilar to adult expression; thus broadening the applicability of
our findings. Targeted TrxR1 inhibition that elicits Nrf2-de-
pendent antioxidant responses represents a novel clinical
therapeutic strategy for preventing or attenuating oxidant-
mediated lung injury.
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deoxyribonucleotides by donating reducing equivalents to
ribonucleotide reductase, is a general intracellular protein
disulfide reductant, and regulates the expression of various
enzymes and transcription factors (2,16,17). In fetal and adult
murine lungs and in adult human lungs, Trx1 and TrxR1 are
predominantly expressed in ciliated and non-ciliated (Clara)
conducting airway epithelial cells (10,13,23,36).
The induction of antioxidant response genes via antioxi-
dant response element (ARE) activation in promoter/en-
hancer regions of target genes enhances survival from
oxidative insults (20,29). ARE activation is primarily medi-
ated by nuclear factor E2-related factor 2 (Nrf2), leading to
the increased transcription of genes that provide direct anti-
oxidants, increase glutathione (GSH) levels, and stimulate
nicotinamide adenine dinucleotide phosphate synthesis (29).
Kelch ECH associating protein-1 (Keap1) controls Nrf2 acti-
vation and nuclear accumulation by binding to the Nrf2
protein and targeting it for proteosomal degradation (20).
Recent studies suggest that reactive oxygen species mitigate
Keap1-mediated Nrf2 degradation via the intermolecular
disulfide formation with Cys-151 of Keap1, while a simulta-
neous disruption of GSH and Trx1/TrxR1 systems causes
constitutive Keap1 oxidation and Nrf2 stabilization (12).
Furthermore, the genetic ablation of TrxR1 expression in
murine hepatocytes (37), in cultured murine embryonic fi-
broblasts (37), or in murine B-cell lymphomas (25) increases
Nrf2-regulated gene induction. Collectively, these data sug-
gest that disruption of the Trx1/TrxR1 systemmay directly or
indirectly influence Nrf2-dependent responses.
Aurothioglucose (ATG) and auranofin (AFN) are anti-in-
flammatory gold compounds that are clinically used to treat
rheumatoid arthritis and experimentally used to inhibit TrxR1
by irreversibly binding its active site selenocysteine (Sec) (14).
Experimentalmodels utilize the hyperoxic exposure of newborn
or adult mice to investigate the pathogenesis of BPD or ARDS,
respectively. In hyperoxia-exposed adult mice, we have previ-
ously shown that ATG pretreatment persistently inhibits TrxR1
and attenuates lung edema and inflammation (38). Though the
mechanisms responsible for these effects were unclear, our data
suggested that TrxR1 inhibition could be therapeutically bene-
ficial in protecting against oxidant-induced lung injury.
The present studies indicate that Trx1 and TrxR1 protein
expression is predominantly localized to ciliated and non-
ciliated (Clara) epithelia in newborn human and murine
lungs, which is similar to fetal and adult lungs. Using murine-
transformed Clara cells (mtCC) (24), we tested the hypothesis
that TrxR1 inhibition protects against the effects of hyperoxia
via Nrf2-dependent mechanisms. TrxR1 inhibition indeed
caused rapid Nrf2 nuclear accumulation, increased the tran-
scription of ARE-regulated genes, and increased intracellular
GSH levels. Furthermore, our data confirmed that TrxR1 in-
hibition in vivo increased Nrf2 activation in adult murine
lungs. While TrxR1 inhibition did not alter the susceptibility
of cells to the effects of hyperoxia, GSH depletion after TrxR1
inhibition markedly enhanced the hyperoxic susceptibility of
cultured mtCCs. These findings suggest that GSH-dependent
enzyme systems in mtCCs may be of greater importance for
protection against hyperoxia than are TrxR-dependent
FIG. 1. TrxR1 activities in mtCCs after AFN, DNCB, or SFN treatment for 1 h. (A) AFN treatment decreased TrxR1
activity by approximately 90%; (B) DNCB treatment decreased TrxR1 activity by 62%; and (C) SFN treatment decreased
TrxR1 activity by 21% compared with vehicle-treated controls. Data (mean – SEM, n = 3–4) were analyzed by one-way
ANOVA or unpaired t-test with significance noted at p< 0.05 (*different than vehicle control). AFN, auranofin; ANOVA,
analysis of variance; DNCB, dinitrochlorobenzene; mtCC, murine transformed Clara cells; SEM, standard error of the mean;
SFN, sulforaphane; TrxR1, thioredoxin reductase-1.
FIG. 2. Nrf2 nuclear abundance and ARE-driven mRNA levels in mtCCs after AFN, DNCB, or SFN treatment and ARE-
luciferase activity in mtCCs treated with TrxR1-specific siRNA. (A) Representative Western blot. (B) AFN, DNCB, and SFN
treatment increased nuclear Nrf2 abundance by 30-fold, 18-fold, and 15-fold, respectively, compared with vehicle-treated
controls. Data (mean– SEM, n = 5–8) were normalized to nucleolin and analyzed by one-way ANOVA with Bonferroni post
hoc with significance noted at p < 0.05. (*different than vehicle; $different than AFN). (C–F) mtCCs were treated with 1 lM
AFN or 15 lM DNCB for 1 h. qRT-PCR analyses indicated greater levels of (C) HO-1, (D) NQO1, (E) TrxR1, and (F) GCLM
after AFN and DNCB treatment than in vehicle-treated controls. Analyses indicated the independent effects of AFN and
DNCB and an interaction between AFN/time and DNCB/time for HO-1, NQO1, TrxR1, and GCLM. dCt values (mean –
SEM, n = 3) were analyzed by two-way ANOVA with Bonferroni post hoc with significance noted at p < 0.05. (*different than
same time/vehicle;%different than same time/AFN; $different than same treatment/0 h; #different than same treatment/5 h).
(G) mtCC were transfected with TrxR1-specific siRNA or empty vector control, ARE-luciferase, and respiratory syncytial
virus-b-galactosidase plasmid DNA for 48 h. Luciferase activity was 2.7-fold greater in the TrxR1 siRNA-treated cells than in
empty vector-treated controls. Data (mean – SEM, n = 9) were normalized to b-galactosidase and analyzed by an unpaired
t-test with significance noted at p< 0.05 (*different than empty vector control). ARE, antioxidant response element; GCLM,
glutamate-cysteine ligase modifier subunit; HO-1, heme oxygenase 1; NQO1, NADPH:quinone oxidoreductase 1; Nrf2,
nuclear factor E2-related factor 2; qRT-PCR = quantitative reverse transcriptase–polymerase chain reaction.
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systems and that TrxR1 inhibition can upregulate GSH sys-
tems above basal levels via Nrf2 activation.
Results
Trx1 and TrxR1 are predominantly expressed
in conducting airway epithelial cells in newborn
human and murine lungs
Immunohistochemical analyses were performed on se-
quential lung sections prepared from a single 1 day-old term
newborn human or a 1 day-old term newborn mouse
to evaluate the expression levels of Trx1 (Supplementary
Fig. S1A–D; Supplementary Data are available online at
www.liebertpub.com/ars) and TrxR1 (Supplementary Fig.
S1E–H) proteins. Trx1 and TrxR1 immunostaining was most
intense in both ciliated and non-ciliated airway epithelial cells
in newborn human and newborn murine lungs, though the
availability of human tissues limited our assessment to one
sample. Trx1 and TrxR1 staining in alveolar epithelia was
comparatively less intense. This indicated that Trx1 and
TrxR1 protein expression was highly enriched in airway epi-
thelia, including lung Clara cell populations.
Selenium supplementation enhances TrxR1 activities
The Sec residue in the TrxR1 C-terminal active site directly
contributes to its catalytic function (1). To ensure adequate se-
lenium saturation for TrxR1 synthesis, mtCCs were supple-
mented with increasing concentrations of selenium (as sodium
selenite). Dose-dependent increases in TrxR1 activities in sup-
plemented mtCCs were detected, with TrxR1 activities in
mtCCs supplemented with sodium selenite at concentrations
above 25nM not being significantly different from each other
(Supplementary Fig. S2). Media were, therefore, supplemented
with 25nM sodium selenite in all subsequent experiments.
TrxR1 activities are decreased by AFN,
dinitrochlorobenzene, and sulforaphane
We previously found that the TrxR1 inhibitor ATG atten-
uated hyperoxic lung injury in adult mice (38). Therefore, we
sought to determine whether Nrf2 activation could be in-
volved by studying the effects of TrxR1 inhibitors AFN and
dinitrochlorobenzene (DNCB) and the well-characterized
Nrf2 inducer sulforaphane (SFN). Our data revealed that AFN
(Fig. 1A), DNCB (Fig. 1B), and sulforaphane (SFN) (Fig. 1C) all
significantly decreased TrxR1 activities in mtCC lysates after
1 h treatment. Lysate TrxR1 activities were approximately
90% lower in AFN-treated cells, 62% lower in DNCB-treated
cells, and 21% lower in SFN-treated cells than in vehicle-
treated controls. Since TrxR1 activities in cells treated with 1
or 2 lM AFN were not significantly different, 1lM AFN was
used for subsequent experiments. TrxR1 activities in AFN-
treated mtCCs were not different than in vehicle-treated
controls 24 h after AFN treatment for 1 h (data not shown).
These data indicate that 1 h treatment of mtCCs with AFN,
DNCB, or SFN significantly inhibits TrxR1 activity.
TrxR1 inhibition increases nuclear Nrf2 levels
To determine whether transient TrxR1 inhibition alters
Nrf2 responses, Western blot analyses for Nrf2 were per-
formed on nuclear fractions from mtCCs treated with 1lM
AFN, 15lMDNCB, or 5lM SFN for 1 h (Fig. 2). AFN, DNCB,
and SFN increased nuclear Nrf2 protein levels by 30-, 18-, and
15-fold, respectively, comparedwith control-treated cells (Fig.
2B). Nuclear Nrf2 protein accumulation was still apparent 2 h
post-AFN or DNCB treatment, while levels no longer differed
from vehicle-treated controls at 5 h (data not shown).
TrxR1 inhibition increases ARE-mediated gene
transcription and intracellular GSH levels
Quantitative reverse transcriptase-mediated polymerase
chain reaction (qRT-PCR) was utilized to assess the mRNA
levels of ARE-regulated genes after the AFN or DNCB
treatment of mtCCs for 1 h. Two-way analysis of variance
(ANOVA) indicated the independent effects of AFN and
DNCB treatment and time-dependent induction in transcripts
of heme oxygenase 1 (HO-1), NADPH:quinone oxidoreduc-
tase 1 (NQO1), TrxR1, and glutamate-cysteine ligase modifier
subunit (GCLM). In vehicle-treated mtCCs, baseline HO-1,
NQO1, TrxR1, andGCLMmRNA levels were*50% less than
the baseline at 5 h (Fig. 2C–F). The HO-1 transcripts were
similarly elevated by AFN and DNCB immediately after
treatment, further elevated 2 h post-treatment, and returned
to baseline levels by 5 h (Fig. 2C). NQO1 transcripts were in-
creased two-fold by AFN immediately after treatment, were
elevated byAFN andDNCB 11 and 9-fold, respectively, at 2 h,
and remained elevated at 5 h (Fig. 2D). Increases in TrxR1
mRNAs were most pronounced at 2 h after AFN or DNCB
treatment (Fig. 2E). In AFN-treated cells, GCLM transcripts
were increased two-fold immediately after treatment, three-
fold 2 h post-treatment, and returned to baseline at 5 h. DNCB
increased GCLM transcripts by 2 h (Fig. 2F).
To determine whether TrxR1 knockdown increases Nrf2-
mediated responses, mtCCs were transiently transfected with
pU6-m3 control or siTR1-3 plasmids. siTR1-3 robustly knocks
down TrxR1 expression in murine lung cells (40). Due to
low transfection efficiency (5%–10%), the mtCCs were co-
transfected with ARE-driven luciferase plasmids to assess
Nrf2 activation. ARE-luciferase promoter activity was 2.7-
fold greater in lysates from siTR1-3-treated cells than in
pU6-m3-treated controls (Fig. 2G).
TrxR1 inhibition increases total GSH levels in mtCCs
in hyperoxia
We determined whether increased GCLM transcription
correlated with increased intracellular GSH contents by
measuring the total GSH levels in mtCC lysates after treat-
ment with 1lM AFN or 15 lM DNCB treatment for 1 h (Fig.
3A). Two-way ANOVA indicated the independent effects of
AFN and DNCB treatment and interactions between AFN/
time and DNCB/time on GSH levels. In DNCB-treated
cells, intracellular GSH contents were 72% less immediately
after treatment than in vehicle-treated controls; however, at
5 h, the GSH contents were 29% greater. The GSH contents in
AFN-treated cells were 33% greater at 5 h. GSH reductase
activities in AFN or DNCB-treated cells were not different
than in vehicle-treated controls at any time point tested (data
not shown).
To determine the effect of hyperoxic exposure on GSH
contents, total GSH levels were determined in vehicle, AFN-
treated, or SFN-treated mtCCs after exposure to room air
1410 LOCY ET AL.
(21% O2, RA) or hyperoxia (85% O2) for 5 or 24 h. Two-way
ANOVA indicated independent effects of AFN and SFN
treatment on GSH levels at 5 h (Fig. 3B). Hyperoxic expo-
sure for 5 h increased the GSH levels in AFN-treated cells
by 31% and in SFN-treated cells by 21% compared with
hyperoxia-exposed controls. Two-way ANOVA indicated
effects of AFN treatment and exposure and SFN treatment
and exposure at 24 h (Fig. 3C). The GSH contents in vehicle-
treated hyperoxia-exposed mtCCs were 25% greater at 24 h
compared with RA-exposed controls. The GSH levels in
hyperoxia-exposed AFN-treated mtCCs were 16% greater
than in vehicle-treated controls at 24 h. The SFN-induced
increases in GSH levels were comparable to those elicited
by AFN treatment.
GSH depletion but not AFN treatment increases
the susceptibility of mtCCs to hyperoxic exposure
To determine the effect of transient TrxR1 inhibition on
cell viability, mtCCs were treated with 1lM AFN for 1 h.
AFN was removed, the cells were washed, and new media
were applied containing vehicle or buthionine sulfoximine
(BSO), which inhibits c-glutamyl cysteine ligase, the rate-
limiting step in GSH synthesis (27). After exposure to RA or
hyperoxia for 24 h, cell viability was assessed by trypan blue
exclusion (Fig. 4A) and ATP contents (Fig. 4B). By trypan blue
exclusion, AFN treatment reduced the viable cell numbers in
RA by 28%, while no differences in ATP contents were de-
tected. In the analyses of RA-exposed cells, viability was
significantly lower in BSO-treated cells than in the vehicle-
treated controls, as determined by trypan blue exclusion and
was not different than AFN treatment alone. The combination
of AFN followed by BSO reduced the viable cell numbers by
89% compared with vehicle-treated controls by trypan blue
exclusion (Fig. 4A). Furthermore, the ATP contents after RA
exposure were 49% lower in AFN-treated mtCCs treated with
BSO than in similarly exposed vehicle-treated controls. In RA,
neither AFN treatment nor BSO treatment significantly al-
tered cell numbers compared with vehicle treatment (Fig. 4B).
Hyperoxic exposure decreased viable cell numbers in all
treatment groups when compared with corresponding RA
control groups, as assessed by trypan blue exclusion (Fig. 4A).
AFN treatment alone did not alter viable cell numbers after
24 h of hyperoxic exposure, whereas the addition of BSO to
the culture medium after AFN treatment diminished viable
cell numbers by greater than 99%. The effect of BSO on cellular
ATP contents in hyperoxia revealed similar trends to viability
assessments using trypan blue exclusion (Fig. 4B). After hy-
peroxic exposure, ATP contents were 79% less in the BSO-
treated group than in vehicle-treated controls. AFN treatment
followed by BSO treatment decreased ATP contents by an
additional 9%.
To determine whether hyperoxic exposure, BSO, and/or
AFN treatment was associated with loss-of-cellular-membrane
integrity, lactate dehydrogenase (LDH) levels in cell media
were measured in all treatment groups (Fig. 4C). In RA, the
combination of AFN and BSO treatment increased LDH levels
by 1.5-fold compared with vehicle-treated controls. Hyper-
oxic exposure in the presence of BSO increased media LDH
levels by 61% and 59%, respectively, when compared with
similarly treated RA and hyperoxia-exposed controls. Fur-
thermore, media LDH levels in hyperoxia-exposed mtCCs
FIG. 3. Total GSH contents in mtCCs after AFN or DNCB
treatment and in RA or hyperoxia-exposed mtCCs after
AFN or SFN treatment. (A) Total GSH contents were greater
in AFN- or DNCB-treated mtCCs 5 h after treatment than in
vehicle-treated controls. Analyses indicated the independent
effects of and an interaction between treatment and time on
GSH levels. Data (mean – SEM, n = 6) were analyzed by two-
way ANOVA with Bonferroni post hoc with significance no-
ted at p< 0.05 (*different than same time/vehicle; %different
than same time/AFN; $different than same treatment/0 h;
#different than same treatment/2 h). (B, C) mtCCs were
treated with 1lM AFN or 5 lM SFN for 1 h, as described in
Methods and exposed to RA or hyperoxia for (B) 5 h or (C)
24 h. Analyses of total GSH levels indicated an independent
effect of AFN and SFN treatment at 5 h and the effects of
treatment and exposure at 24 h. Data (mean – SEM, n = 4–6)
were analyzed by two-way ANOVA with Bonferroni post hoc
with significance noted at p< 0.05 (*different than vehicle/
21% O2;
$different than vehicle/85% O2;
#different than same
treatment/21% O2). GSH, glutathione; RA, room air; SFN,
sulforaphane.
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treated with both AFN and BSO were 90% greater than in
hyperoxia-exposed controls.
ATG administration in vivo increases lung NQO1
expression in adult mice
To determine whether systemic TrxR1 inhibition by ATG
in vivo was associated with lung Nrf2 activation, we injected
adult C3H/HeN mice with 0, 25, 100, or 200mg/kg ATG in
saline and measured lung TrxR1 activities and NQO1 mRNA
levels at 24 h. Compared with controls, lung TrxR1 activities
were decreased by 82%, 90%, and 95% after the administra-
tion of 25, 100, or 200mg/kg ATG, respectively (Fig. 5). Fur-
thermore, 25, 100, or 200mg/kg ATG increased lung NQO1
mRNAs by 0.5, 1.2, and 2.3-fold, respectively, at 24 h. No ef-
fect of ATG treatment on total lung GSH levels was detected
after 24 h ATG treatment (data not shown).
Discussion
The major findings in the present studies are as follows: (1)
TrxR1 inhibition induces Nrf2 responses in mtCCs; (2) SFN
inhibits TrxR1 activity in mtCCs; (3) AFN-treated mtCCs are
not more susceptible than vehicle-treated cells to the effects of
hyperoxia; (4) mtCC viability in hyperoxia is highly depen-
dent on GSH; and (5) ATG treatment in vivo inhibits TrxR1
and induces the Nrf2 target gene NQO1 in adult mouse lungs.
Our studies also indicate that TrxR1 is highly enriched in
newborn human and mouse airway epithelia, though these
findings require confirmation in a greater number of samples.
The activation of Nrf2-dependent antioxidant responses on
TrxR1 inhibition provides a plausible mechanism for our
previous findings of attenuated hyperoxic lung injury in vivo
after the TrxR1 inhibition by ATG (38). We speculate that the
protective effects of TrxR1 inhibition on hyperoxia-induced
lung injury in vivo are likely GSH dependent and mediated
via Nrf2. Our data also indicate that SFN, a well-described
Nrf2 inducer, also inhibits TrxR1, suggesting that TrxR1 in-
hibition may be a common feature of Nrf2 inducers, as
FIG. 4. Viable cell numbers, ATP contents, and media
LDH levels after AFN treatment of mtCCs and exposure to
RA or hyperoxia for 24 h in the presence or absence of
BSO. mtCCs were treated with 1 lM AFN for 1 h, media
changed, and subsequently exposed to RA or 85% O2 for 24 h
in the presence or absence of 0.25mM BSO. (A) The addition
of 0.25mM BSO to the culture medium of AFN-treated cells
decreased viable cell numbers in both RA and hyperoxia, as
assessed by trypan blue exclusion. (B) ATP contents were
lower in AFN-treated cells cultured in RA and hyperoxia in
the presence of BSO. (C) Media LDH levels were greater
in AFN-treated mtCCs cultured in RA or hyperoxia than in
vehicle-treated mtCCs cultured under similar conditions.
Data (mean – SEM, n= 9–12) were analyzed by Kruskal–
Wallis followed by Dunn’s post hoc with significance noted at
p < 0.05 (*different than vehicle/RA; #different than vehicle/
O2;
Udifferent than same treatment/RA; $different than
AFN/O2;
¢different than AFN/RA; edifferent than BSO/
RA). BSO, buthionine sulfoximine; LDH, lactate dehydro-
genase.
FIG. 5. TrxR1 activities and NQO1 expression in adult
murine lungs 24h after ATG administration. Adult C3H/
HeN mice were treated with a single intraperitoneal injection
of 0, 25, 100, or 200mg/kg ATG in saline as described in
Materials andMethods. ATG treatment caused dose-dependent
decreases in lung TrxR1 activities of approximately 95%.
Lung NQO1 mRNA levels were increased by approximately
2.5-fold in ATG-treated mice. Data (mean– SEM, n= 3) were
analyzed by two-way ANOVA followed by one-way ANOVA
with Bonferroni post hoc with significance noted at p< 0.05
(*TrxR1 activity different than control; #NQO1 levels differ-
ent than control). ATG, aurothioglucose.
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previously discussed (1). The lack of a protective effect in
mtCCs highlights the complexities of investigating cellular
redox systems using immortalized cells in isolated culture
systems, but their strong GSH dependence is consistent with
our proposed model.
AFN was chosen to pharmacologically inhibit TrxR in
mtCCs, because it is more stable in solution, requires lower
concentrations for complete inhibition (15), andmore strongly
induces Nrf2/ARE responses in vitro than does ATG (19). The
transcriptional induction of TrxR1 after 1 h AFN treatment
(Fig. 2E) and equivalent TrxR1 activities in AFN-treated and
control-treated mtCCs at 24 h suggests the recovery of TrxR1
reductive capacities in mtCCs; likely through the synthesis of
new enzyme. This is in contrast to our previous studies
in vivo in which the long half-life and high level of protein
binding by ATG ensured the inhibition of newly synthesized
TrxR1 by residual drug (38). We, therefore, speculate that
ATG attenuates hyperoxic lung injury in vivo by inducing
sustained Nrf2-mediated antioxidant responses.
Increased Nrf2-mediated antioxidant responses (Fig. 2C–
E), including increased intracellular GSH levels (Fig. 3A), in
AFN-treated or DNCB-treated mtCCs are consistent with the
recent reports on the constitutive activation of Nrf2-driven
antioxidant responses in TrxR1-deficient hepatocytes (37).
Furthermore, our data confirm that the treatment of mtCCs
with TrxR1-specific siRNA also induces Nrf2-mediated re-
sponses (Fig. 2G). While lower GSH levels in mtCCs early
after DNCB treatment are likely attributable to DNCB con-
jugationwithGSH catalyzed by glutathione S-transferases (4),
sustained increases in GSH levels after AFN or SFN treatment
(Fig. 3B, C) are most likely mediated by Nrf2 activation.
Keap1 oxidation and Nrf2 stabilization are increased after the
simultaneous impairment of Trx1/TrxR1 and GSH pathways
in cells, which stably express TrxR1-specific shRNA (12) and
in hepatocytes with a genetic defect in TrxR1 expression (37),
suggesting that Nrf2 activation can be redox regulated by
Trx1/TrxR1 and/or GSH systems. It is likely that the cells in
the above-referenced studies adapt to TrxR1 deficiency
through the up-regulation of compensatory mechanisms.
Our findings demonstrate that compensation for pharmaco-
logically induced TrxR1 deficiency can be rapid.
Nrf2 is integral to pulmonary responses to hyperoxia. It
was identified as a candidate gene that regulates hyperoxic
lung injury (8) and a NRF2 promoter polymorphism corre-
lates with increased susceptibility to acute lung injury in
humans (26). Conventional Nrf2 knockout mice are more
susceptible to hyperoxic lung injury (7) and display impaired
resolution of lung injury and inflammation after a nonlethal
hyperoxic insult; though GSH administration immediately af-
ter the exposure attenuates this damage (30). Clara cell-specific
Nrf2 knockout mice exhibit exacerbated hyperoxic lung injury
and impaired inflammatory resolution processes during re-
covery (31), highlighting the importance of Clara cells in
pulmonary responses to hyperoxia. 2-cyano-3,12-dioxooleana-
1,9(11)-dien-28-oyl (CDDO)-imidazole, which disrupts the
cytosolic Keap1:Nrf2 interaction, robustly induces lung anti-
oxidant gene expression (39), and intermittent administration
of CDDO-imidazole during hyperoxic exposure induces Nrf2
antioxidant responses and attenuates lung injury (32). Collec-
tively, these data indicate important roles for Clara cell-specific
Nrf2 signaling during hyperoxic injury and repair, identifying
Nrf2 as a promising therapeutic target.
In the current studies, AFN-treated mtCCs were not more
susceptible to hyperoxia than controls, despite the significant
inhibition of cellular TrxR1 activity. Dramatic decreases in
mtCC viability after BSO, but not AFN treatment, implies that
GSH is more important than Trx1/TrxR1 in promoting mtCC
viability in hyperoxia. The reasons for the discrepancies be-
tween our previous in vivo finding of attenuated hyperoxic
lung injury after ATG treatment (38) and the lack of protection
of mtCCs by AFN are likely complex and illustrate the im-
portance of cell-to-cell communication toward hyperoxic lung
injury in vivo that is not easily replicated in isolated cell-
culture systems. Taken together, however, we conclude that
the augmentation of GSH systems through Nrf2 activation
may protect against oxidant lung injury. If pulmonary Nrf2
activation can be accomplished via drug-mediated TrxR1 in-
hibition, which seems to be without detrimental effects, then
this approach could constitute a novel strategy for attenuating
pulmonary oxidant lung injury. Similar expression patterns of
Trx1 and TrxR1 proteins in newborn and adult mouse or
human lungs broaden the clinical applicability of the present
findings to both BPD and ARDS. If successful, such treat-
ments are of crucial clinical importance and, thus, need to be
studied further.
Materials and Methods
Immunohistochemistry
Human tissues from an infant who died in the intensive
care nursery were processed within 6 h of death under pro-
tocols approved by the Institutional Review Board of the
Strong Memorial Hospital (Rochester, NY). Animal protocols
were approved by the Institutional Animal Care and Use
Committee of The Research Institute at Nationwide Chil-
dren’s Hospital. RA-raised 1 day C3H/HeN pups were eu-
thanized using intraperitoneal (i.p.) ketamine/xylazine (150/
15mg/kg). Inflation-fixed lungs (formalin at 20 cm H2O,
5min) were paraffin embedded, and sectioned. For Trx1, the
slides were incubated for 5min in 3% H2O2 solution to block
endogenous peroxidase activity. The slides were then incu-
bated with monoclonal rabbit anti-human Trx1 primary an-
tibody (#2429, Cell Signaling, Danvers, MA; 1:100) followed
by biotinylated goat anti-rabbit secondary antibody (BA-1000,
Vector Laboratories, Burlingame, CA; 1:200) and were de-
veloped using a Vectastain Elite kit (Vector Laboratories).
Antibody binding was visualized with diaminobenzamidine
(DAB). For TrxR1, the slides were deparaffinized, rehydrated,
heated to 90C in 100mM sodium citrate, pH 6.0, for 30min,
and cooled to room temperature. The slides were incubated
with 1.5% H2O2 for 10min to block endogenous peroxidase
activity and were incubated in rabbit anti-mouse TrxR1 an-
tiserum (Dr. Gary Merrill, Oregon State Univeristy; 1:50) fol-
lowed by horseradish peroxidase-conjugated goat anti-rabbit
secondary antibody (#13859.012, Invitrogen, Carlsbad, CA;
1:1200). Antibody binding was visualized with DAB.
Cell culture and treatments
mtCCs (Dr. Franco DeMayo, Baylor University) were cul-
tured in 1·Dulbecco’s modified Eagle’s medium with 4.5 g/l
glucose, L-glutamine and sodium pyruvate, 10% fetal bovine
serum, 1% penicillin-streptomycin (Mediatech, Manassas,
VA), and 25 nM sodium selenite (Sigma Chemical Co.,
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St. Louis, MO), except as indicated in Supplementary Figure
S2. The cells were plated at equal densities, allowed to adhere
overnight, and treated with dimethyl sulfoxide (Fisher
Scientific, Pittsburgh, PA) control, AFN (Sigma), DNCB
(Sigma), or SFN (LKT Laboratories, Inc., St. Paul, MN) for 1 h
in serum-free media followed by three washes with Dulbec-
co’s phosphate-buffered saline. The cells were either collected
or cultured in freshmediawithout an inhibitor and exposed to
RA or 85% O2 in oxygen-controlled incubators (Biospherix,
Lacona, NY). For a subset of experiments, 4 ll/ml of 6.25mM
BSO (Sigma, 0.25mM final concentration) or 4 ll/ml Dul-
becco’s phosphate buffered saline was added to the media
after AFN removal.
TrxR1 activities and GSH levels
TrxR1 activities in cell lysates were determined as previ-
ously described (6,33). The GSH concentrations of cell lysates
were determined as previously described (38).
Nuclear fraction preparation and Western blot
mtCCs treated with AFN, DNCB, or SFN for 1 h were col-
lected and lysed in sucrose buffer (0.32 M sucrose, 10mM
Tris-HCl, pH 8.0, 3mM CaCl2, 2mM magnesium oxaloace-
tate, 0.1mM ethylenediaminetetraacetic acid [EDTA],
0.5% Nonidet P-40, 1mM dithiothreitol, and 0.5mM PMSF
[phenylmethylsulfonyl fluoride]). Lysates were centrifuged
for 5min at 500 g at 4C, and the supernatant (cytoplasmic
fraction) was removed. Nuclei were washed in sucrose buffer
without Nonidet P-40 and were centrifuged as just de-
scribed. After supernatant removal, the nuclear pellet was
resuspended in 30ll of hypotonic buffer (20mM HEPES, pH
7.9, 1.5mM MgCl2, 20mM KCl, 0.2mM EDTA, 25% glycerol
(v/v), 0.5mM dithiotreitol [DTT], and 0.5mM PMSF). Hy-
pertonic buffer (30 ll; 20mM HEPES, pH 7.9, 1.5mM MgCl2,
800mM KCl, 0.2mM EDTA, 25% glycerol (v/v), 1% Nonidet
P-40, 0.5mM DTT, 0.5mM PMSF, and 4.0 lg/ml each of
leupeptin, aprotinin, and pepstatin) was slowly added. Pro-
tein concentrations were determined using a Bio-Rad Protein
Assay Kit. Samples were separated on 4%–12% bis-tris gels
(Invitrogen), transferred to nitrocellulose membranes (iBlot,
Invitrogen), blocked with 10% milk/tris-buffered saline con-
taining 1% Tween-20 (TBS-T), and probed using a polyclonal
rabbit anti-Nrf2 antibody (H-300, Santa Cruz Biotechnology,
Santa Cruz, CA; 1:500) in TBS-T followed by goat anti-rabbit
immunoglobulin G-horseradish peroxidase secondary anti-
body (Bio-Rad, Hercules, CA; 1:12,000) in TBS-T. Membranes
were developed using enhanced chemiluminescence (GE
Healthcare, Buckinghamshire, UK). As a loading control,
membranes were re-probed with polyclonal rabbit anti-
nucleolin antibody (ab22758,Abcam,Cambridge,MA; 1lg/ml).
Quantitative real-time PCR
RNA was isolated from mtCCs or lungs using TRIzol
(Invitrogen) and the RNeasy Mini Kit (Qiagen, German-
town, MD). cDNAs were synthesized using Oligo d(T)
primers, the Superscript III Reverse Transcriptase Kit (In-
vitrogen), and dNTPs (Fisher). Primers for murine TrxR1 (18),
HO-1 (22), NQO1 (11), GCLM (21), and b-actin (35) (In-
tegrated DNA Technologies, San Diego, CA), SYBR green/
ROX master mix (Superarray, Frederick, MD) and cDNAs
were loaded into 96-well plates, and Ct values were obtained
using an ABI 7500 Real-time PCR System (Applied Biosys-
tems, Carlsbad, CA). The Ct values were normalized to b-
actin. Fold changes were calculated using 2( -ddCt).
ARE luciferase analyses
mtCCswere transiently transfectedwith siTR1-3 or pU6-m3
control plasmid (Dolph Hatfield, NIH), pGL2 (basic) 3xARE
Lux ( Joan Massague, Memorial Sloan Kettering, Addgene #
14934), and respiratory syncytial virus (RSV)-b-galactosidase
(Dr. Y. Liu, Nationwide Children’s). Cells were co-transfected
at 60% confluence with 12lg plasmid DNA per well (6lg
3xARE:RSV-bgal [25:1] and 6lg of siTR1-3 or control plasmid)
on 9.6-cm2 tissue-culture plates using JetPEI (Polyplus-Trans-
fection) according to the manufacturer’s instructions. ARE-lu-
ciferase and b-glactosidase activities in cell lysates were
determined 48 h after transfection using the Luciferase Re-
porter Assay System and the b-Galactosidase Enzyme Assay
System (Promega), respectively, and a Veritas Microplate
Luminometer (Promega).
Cell viability
Viable cell numbersweredeterminedby trypanblue exclusion
and by ATP contents by CellTiter-Glo assay (Promega Corp.,
Madison, WI). Media LDH levels were determined as follows:
100ll of test mixture (216lM nicotinamide adenine dinucleotide
(NADH) in 60mM K-phosphate buffer, 0.72mM pyruvate, pH
7.5) was added to 200ll of themedia, andNADHoxidationwas
recorded at 340nm for 5min using a SpectramaxM2 (Molecular
Devices, Sunnyvale, CA).
ATG administration in vivo
Adult C3H/HeNmice (6–8weeks, n = 3) received single i.p.
injections of 0, 25, 100, or 200mg/kg ATG (Research Diag-
nostics, Flanders, NJ) in saline and were euthanized 24 h after
the injection using i.p. ketamine/xylazine (150/15). Lungs
were removed and placed in TRIzol on dry ice. A portion of
the left lung was homogenized using TissueLyser II (Qiagen).
Statistical analyses
Data were analyzed using GraphPad Prism software (La
Jolla, CA), were tested for homogeneity of variances, and
were log transformedwhen indicated. Data were analyzed by
the unpaired t-test, one-way ANOVA, or two-way ANOVA
followed by Bonferroni post hoc. Nonparametric data were
analyzed by Kruskal–Wallis followed by Dunn’s post hoc.
Significance was noted at p < 0.05.
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Abbreviations Used
AFN¼ auranofin
ANOVA¼ analysis of variance
ARDS¼ acute respiratory distress syndrome
ARE¼ antioxidant response element
ATG¼ aurothioglucose
BPD¼ bronchopulmonary dysplasia
BSO¼ buthionine sulfoximine
CDDO¼ 2-cyano-3,12-dioxooleana-1,9(11)-dien-
28-oyl
DAB¼diaminobenzamidine
DNCB¼dinitrochlorobenzene
DTT¼dithiotreitol
EDTA¼ ethylenediaminetetracetic acid
GCLM¼ glutamate-cysteine ligase modifier
subunit
GSH¼ glutathione
i.p.¼ intraperitoneal
H2O2¼hydrogen peroxide
HO-1¼heme oxygenase 1
Keap1¼Kelch ECH associating protein-1
LDH¼ lactate dehydrogenase
mtCC¼murine transformed Clara cells
NADH¼nicotinamide adenine dinucleotide
NADPH¼nicotinamide adenine dinucleotide
phosphate
NQO1¼NADPH:quinone oxidoreductase 1
Nrf2¼nuclear factor E2-related factor 2
PCR¼polymerase chain reaction
PMSF¼phenylmethylsulfonyl fluoride
qRT-PCR¼ quantitative reverse transcriptase–PCR
RA¼ room air
RSV¼ respiratory syncytial virus
Sec¼ selenocysteine
SEM¼ standard error of the mean
SFN¼ sulforaphane
TBS-T¼ tris-buffered saline with 1% Tween 20
Trx1¼ thioredoxin-1
TrxR1¼ thioredoxin reductase-1
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